Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This correspondence discusses different approaches to managing patients on the anti-platelet medication Plavix and reports no new clinical results.

This review discusses hypersensitivity reactions to anticoagulants like ASA and heparins, highlighting their rare but potentially life-threatening nature, and emphasizes the need for meticulous allergy testing to find safe alternatives.

Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.

This chapter reviews drugs affecting blood coagulation and details the increased hemorrhage risk associated with warfarin interactions, liver disease, heart failure, and antiphospholipid antibodies but reports no new clinical results.

Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.

This article discusses bridging anticoagulation for patients interrupting warfarin for surgery and highlights the need for the BRIDGE randomized trial to address current uncertainties about its effectiveness and safety.

This study found that elderly patients with acute coronary syndrome had higher PRU rates, and ticagrelor showed greater antiplatelet efficacy compared to clopidogrel in this population.

This review outlines the steps of contemporary hair transplantation surgery, including the roles of medications and nonsurgical options, but it reports no new clinical findings.

This article reviews complications associated with modern hair transplant surgery and discusses their treatment and prevention but reports no new clinical results.

This review discusses the current procedure for follicular unit hair transplantation, emphasizing its natural and reproducible results, but does not report new clinical findings.

This study constructed a panel of pharmacokinetic and pharmacodynamic genes, revealing that current SNP chips insufficiently capture many drug-response gene variants, highlighting the need for complementary genetic approaches.

This article discusses the surgical technique of hair transplantation in women and offers insights on postoperative care and planning for improved patient outcomes, without presenting new clinical findings.

This study found that while GPT-4 shows high accuracy and efficiency in clinical decision making, physicians' critical thinking and lifelong learning skills remain essential, particularly in addressing and interpreting AI errors in medical settings.

This review covers the current procedure for follicular unit hair transplantation, noting that recent advancements have made the results natural and undetectable, but it presents no new experimental findings.

This review discusses U.S. patents in organic process development published in July and August 2004 and reports no new experimental results.

In this study, oral tranexamic acid significantly improved melasma in 40 female patients over three months, with no adverse effects like post-inflammatory hyperpigmentation or bleeding, demonstrating its potential as a safe and effective treatment option.

This review discusses common mistakes in follicular unit transplantation and provides guidance for practitioners to enhance patient outcomes, but reports no new clinical results.

This review examines recent advancements in electrospun nanofibers for wound healing applications, but reports no new experimental results, highlighting their potential in sutures, dressings, and skin regeneration.

This study found that "micro skin tissue columns" improved wound healing by enhancing re-epithelialization, collagen deposition, dermal remodeling, and reducing inflammation without causing long-term donor site morbidity.

This study found that sericin dressing containing collagen hydrolysate significantly reduced wound healing time and improved scar quality compared to commercial dressing in split-thickness skin graft donor sites.

In this study, researchers found that niosomes, bilosomes, and spanlastic formulations can enhance the oral anticoagulation efficiency of rivaroxaban in rats, with spanlastic ranked as the most effective in prolonging clotting, prothrombin, and tail bleeding times compared to unprocessed rivaroxaban.

This review discusses evidence from recent clinical trials showing inclisiran effectively lowers LDL cholesterol levels in patients with cardiovascular disease, leading to its use in the UK despite not being approved by the FDA.

Different cells affect hair follicle blood vessels, endothelial cells react differently to inflammation and oxidized fats, and prasugrel better protects heart vessels during a procedure than clopidogrel.

This article highlights that rivaroxaban, commonly associated with bleeding risks, may also cause rare non-bleeding adverse effects like liver injury and hypersensitivity.

This article reviews potential drug and herbal interactions with warfarin that may increase bleeding risk, and reports no new clinical results.

This study found that non-bleeding adverse events associated with NOACs affect multiple organ systems, emphasizing the importance of clinical vigilance. Specific NOACs like dabigatran, apixaban, edoxaban, and rivaroxaban were linked to distinct adverse reactions, including metabolic imbalances, thyroid disorders, and menstrual irregularities.

In this study, the researchers developed a deep learning framework to pre-emptively screen for adverse drug effects, showing strong predictive performance, including for increased bleeding risks with edoxaban compared to other anticoagulants.

This review discusses the introduction of new oral anticoagulants for atrial fibrillation and highlights their safety and the development of reversal agents, but reports no new clinical findings.

A woman had a delayed allergic reaction to the blood thinner enoxaparin, treated with a steroid cream.

This study reported that enoxaparin may cause alopecia in patients treated for cerebral venous thrombosis, with hair growth resuming naturally after the treatment ended.